GRI Bio, Inc. (GRI): Nasdaq/NYSE listing notice — GRI Bio regains compliance with Nasdaq minimum bid price rule

GRI Bio, Inc.

Received Nasdaq notice on March 10, 2025 confirming compliance with Listing Rule 5550(a)(2).
Previously reported bid price deficiency in September 2024 filings.
Company is now in full compliance and subject to no further action from Nasdaq.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

GRI Bio, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 10, 2025, GRI Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price deficiency under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"), which the Company previously reported on in its Current Reports on Form 8-K filed on September 10, 2024 and Form 8-K/A filed on September 11, 2024, has been cured, and that the Company is now in compliance with the Minimum Bid Price Rule.

View on SEC.gov

Browse all listing & compliance notices →

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-25-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.